Monday, October 26, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleCNBC· May 22, 2026

Kevin Warsh's real Fed 'regime change' may happen deep inside Wall Street's plumbing

View original at cnbc.com
Kevin Warsh's real Fed 'regime change' may happen deep inside Wall Street's plumbing Incoming Federal Reserve Chair Kevin Warsh's talk about "regime change" at the central bank has generated speculation about everything from interest rates to major personnel changes to fundamental alterations in the way it operates and…
Opening lines of the source · CNBC · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The Federal Reserve's balance sheet is bloated and could be reduced while simultaneously allowing the Fed to lower interest rates

    60% confidence
  • Under a Warsh Fed, the overnight repo rate could become the primary policy rate, replacing the federal funds rate as the key transmission mechanism for monetary policy

    60% confidence
  • The Federal Reserve could return to a system of scarce reserves and it would work perfectly well, though it would be complicated and must be done slowly

    60% confidence
  • A repo-rate-as-policy-rate framework could let Warsh satisfy Trump's push for lower interest rates while still maintaining tighter underlying financing conditions to combat persistent inflation

    60% confidence
  • Up to $2.1 trillion in balance sheet reductions could be achieved through the current policy framework, with further cuts possible under a scarce reserves approach; the process would take at least a year and quite possibly several

    60% confidence
  • The Fed has never adequately explained when and why it uses asset purchases for monetary policy reasons versus other reasons

    60% confidence
  • Focusing only on balance sheet size is too narrow; duration and composition also matter, and neglecting them could cause increased volatility and more Fed interventions; lowering bank reserve requirements could destabilize the system

    60% confidence
  • The Fed should publicly establish a clear framework for future balance sheet operations so markets can form sensible expectations rather than assuming unlimited intervention

    60% confidence
  • Any changes in the Federal Reserve's balance sheet should be gradual and carefully planned

    60% confidence
  • Political considerations never enter FOMC meeting discussions; this was true even under Alan Greenspan's chairmanship

    60% confidence
  • The Fed balance sheet debate is a medium-term project requiring careful implementation; no one including Warsh argues it can be done rapidly

    60% confidence
  • Shrinking the Fed balance sheet is the wrong objective; proposals to do so would undermine bank resilience, impede money market functioning, threaten financial stability, and some would actually increase the Fed's footprint in financial markets

    60% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biotech Catalyst Window: ESMO Data, the Ivonescimab PDUFA and Small-Cap Delistings
Mid-October to November 2026 is a dense catalyst period for clinical-stage biotech. Positive late-stage readouts (ALOFT-IPF, TELIGAN, MIUDELLA, the duvakitug extension) and the ESMO 2026 presentations lead up to the FDA's 14 November PDUFA date for the ivonescimab BLA. At the opposite end of the market, Spago Nanomedical is moving to delist from Nasdaq First North, which shows how hard it is for micro-cap developers to fund themselves. Value is concentrating in companies with late-stage data and near-term regulatory outcomes.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,500 source documents archived
Query this data → isubstrate.com